Skip Navigation



QJM Advance Access published online on November 3, 2006
QJM, doi:10.1093/qjmed/hcl115
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/12/811    most recent
hcl115v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Palmieri, C.
Right arrow Articles by Bower, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Palmieri, C.
Right arrow Articles by Bower, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: Journals.permissions@oxfordjournals.org

Review

AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy

C. Palmieri 1, T. Treibel 1, O. Large 1, and M. Bower 1 *

1 From the Department of Oncology, Chelsea & Westminster Hospital, London, UK

* To whom correspondence should be addressed.
M. Bower, E-mail: m.bower{at}ic.ac.uk


  Abstract

Highly active antiretroviral therapy (HAART) has had a dramatic effect on the natural history of HIV disease, reducing the incidence of opportunistic infections and Kaposi's sarcoma, and improving overall survival. Since HAART became available in 1996, the incidence of AIDS-related non-Hodgkin's lymphoma (NHL) has fallen, and although there has been no change in the clinical features at presentation, the overall survival of patients with AIDS-related NHL has improved. Prognosis is now determined chiefly by lymphoma-associated factors similar to those in the general population (the International Prognostic Index), although serum CD4 count at lymphoma diagnosis is an additional independent prognostic factor. The management of patients with AIDS-related NHL with either infusional chemotherapy or CHOP-like regimens (cyclophosphamide, doxorubicin, vincristine and prednisolone) achieves response and survival rates approaching those observed in the general population. However, careful attention should be paid to central nervous system chemoprophylaxis, opportunistic infection prophylaxis and potential drug interactions between cytotoxic and antiretroviral therapies. In the era of HAART, the goal of therapy for these patients is now complete remission rather than palliation.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
J.-S. Kim, S. J. Kim, J.-S. Kim, E. S. Kim, H.-J. Shin, J. S. Chung, Y.-H. Min, M. H. Lee, Y. J. Choi, S.-M. Bang, et al.
Report of Aids-related Lymphoma in South Korea
Jpn. J. Clin. Oncol., February 8, 2008; (2008) hym168v1.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.